News

IMMY

​Imprimis (IMMY) Sheds $3M in Expenses By Ceasing Operations at Texas Facility

Bolton Flautt | Equities.com |

Shares of Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) jumped nearly 4 percent to $3.93 per share on moderate volume after announcing an expense reduction program. The company has a market capitalization of $48.9 million and an average daily volume of 35


The Importance of Bringing Affordable Medicine to the Public: An Interview with Imprimis Pharmaceuticals CEO Mark Baum

Joel Anderson | Equities.com |

After Martin Shkreli boosted the price of a crucial treatment by 5,000%, Imprimis Pharmaceuticals (IMMY) countered by offering an alternative for just $1 a pill.


How the Drug Price Scrutiny is Affecting Pharma Stocks

Guild Investment Management | Equities.com |

Last week, shares of pharma roll-up firm Valeant Pharmaceuticals (VRX), which had already been punished in September’s health-care rout, were slammed by accusations of fraud made by


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

INTERVIEW: CEO Steve Stanulis - Stanulis Films

Equities.com's Sam Mitchell interviewing CEO Steve Stanulis of Stanulis Films.